#1 Clinical Trials Search in Europe

Pp1493

A groundbreaking clinical trial is underway to investigate the potential of phage therapy using PP1493, a novel bacteriophage solution, in treating prosthetic joint infections caused by Staphylococcus aureus. This study aims to evaluate the effectiveness and safety of combining PP1493 with standard treatments for patients suffering from hip or knee joint infections. The trial represents a significant step forward in exploring alternative approaches to combat antibiotic-resistant bacterial infections.

Table of Contents

What is PP1493?

PP1493 is an innovative medical treatment being studied for its potential to fight certain types of bacterial infections. It belongs to a class of treatments called phage therapy, which uses viruses (called bacteriophages) that specifically target and kill bacteria.[1] PP1493 is designed as a solution for injection, meaning it can be directly administered into the body where it’s needed most.

Target Condition: Prosthetic Joint Infections

The main focus of PP1493 is treating prosthetic joint infections (PJIs) caused by a specific type of bacteria called Staphylococcus aureus. These infections can occur in patients who have had hip or knee replacement surgery, where bacteria infect the area around the artificial joint.[1] PJIs are serious complications that can cause pain, limit mobility, and sometimes require additional surgeries.

How PP1493 Works

PP1493 works by targeting and destroying Staphylococcus aureus bacteria. Unlike traditional antibiotics that can affect many types of bacteria, PP1493 is designed to be highly specific. This targeted approach may help reduce side effects and the risk of developing antibiotic resistance.[1]

Clinical Trial Details

PP1493 is currently being studied in a clinical trial called PhagoDAIR I. This trial is:

  • A Phase II pilot study
  • Multicenter (conducted at multiple hospitals or clinics)
  • Randomized (patients are randomly assigned to different treatment groups)
  • Double-blind (neither patients nor most of the medical staff know who is receiving which treatment)
The study aims to test PP1493 in combination with standard treatments for prosthetic joint infections.[1]

Potential Benefits of PP1493

If successful, PP1493 could offer several benefits for patients with prosthetic joint infections:

  • Improved infection control: The main goal is to better manage and eliminate the bacterial infection.[1]
  • Reduced need for additional surgeries: By controlling the infection more effectively, PP1493 might help some patients avoid further surgical procedures.[1]
  • Better quality of life: The study will assess how treatment affects patients’ overall well-being and joint function.[1]

Safety Considerations

As with any new medical treatment, safety is a top priority in the PP1493 study. The researchers will closely monitor patients for any side effects or adverse reactions throughout the trial. This includes regular check-ups, blood tests, and assessments of how well the treatment is working.[1]

Patient Eligibility

The study has specific criteria for who can participate. Generally, eligible patients are:

  • Adults (18 years or older)
  • Diagnosed with a Staphylococcus aureus infection in a hip or knee prosthetic joint
  • The infection occurred more than one month after their joint replacement surgery
  • Their infection is suitable for a specific treatment approach called DAIR (Debridement, Antibiotics, and Implant Retention)[1]
There are additional medical criteria that doctors will use to determine if a patient is eligible for the study.

Future Implications

The PhagoDAIR I study with PP1493 is an important step in developing new treatments for prosthetic joint infections. If successful, it could lead to larger studies and potentially a new option for patients struggling with these difficult-to-treat infections. This research may also pave the way for using phage therapy in other types of bacterial infections.[1]

Aspect Details
Study Drug PP1493 (bacteriophage solution)
Target Condition Knee or hip prosthetic joint infection due to Staphylococcus aureus
Study Design Randomized, double-blind, placebo-controlled
Treatment Regimen DAIR + curative antibiotics therapy combined with PP1493 or placebo
Primary Outcome Clinical control of infection (no fever, no worsening pain, no signs of ongoing infection)
Key Eligibility Criteria Adults with Staphylococcus aureus PJI > 1 month post-implantation, susceptible to study phages
Safety Monitoring Adverse events, physical examinations, hematology and biochemistry tests
Secondary Outcomes Quality of life, joint function, hospitalization duration, bacteriological profile

FAQ

  • What is PP1493 and how does it work? PP1493 is a bacteriophage solution designed to target Staphylococcus aureus bacteria. Bacteriophages are viruses that specifically infect and kill bacteria, potentially offering a new way to treat infections, especially those resistant to antibiotics.
  • Who is eligible for this clinical trial? The trial is open to adults (18 years or older) with a Staphylococcus aureus knee or hip prosthetic joint infection that occurred more than one month after prosthesis implantation. Participants must meet specific criteria, including having a strain of bacteria susceptible to at least one of the phages used in the study.
  • What does the treatment involve? The treatment involves a procedure called DAIR (Debridement, Antibiotics, and Implant Retention) combined with curative antibiotic therapy and either PP1493 or a placebo solution. Some patients may receive a single administration of PP1493, while others may receive a saline solution.
  • How long does the trial last? The initial treatment period involves a single administration of either PP1493 or placebo. However, the total duration of participation and follow-up is not specified in the provided information. Patients will be monitored for clinical control of infection and various other outcomes throughout the study period.
  • What are the potential benefits and risks of participating? Potential benefits include improved infection control and joint function. However, as with any clinical trial, there may be risks or side effects. The study aims to assess the safety of the treatment regimen throughout the trial. Patients will be closely monitored for any adverse events or reactions to the treatment.

Ongoing Clinical Trials on Pp1493

  • Study of PP1493 and PP1815 phage therapy for patients with knee or hip joint infections caused by Staphylococcus aureus after prosthetic surgery

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France The Netherlands Spain

  • Study of PP1493 and PP1815 bacteriophages combined with DAIR and antibiotics for treating knee or hip prosthetic joint infections caused by Staphylococcus aureus

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Bacteriophage: A virus that specifically infects and destroys bacteria. In this trial, bacteriophages are being used as a potential treatment for bacterial infections.
  • DAIR: Stands for Debridement, Antibiotics, and Implant Retention. It's a surgical procedure used to treat prosthetic joint infections while keeping the original implant in place.
  • Prosthetic Joint Infection (PJI): An infection that occurs around an artificial joint, such as a hip or knee replacement. In this study, the focus is on PJIs caused by Staphylococcus aureus bacteria.
  • Staphylococcus aureus: A type of bacteria that can cause various infections, including those in prosthetic joints. Some strains of this bacteria can be resistant to certain antibiotics.
  • Phage Therapy: A treatment approach that uses bacteriophages to combat bacterial infections, especially those resistant to traditional antibiotics.
  • Suppressive Antibiotics Therapy (SAT): A long-term antibiotic treatment used to control chronic infections, often used in cases where complete eradication of the infection is challenging.
  • Clinical Control of Infection: In this study, it refers to the absence of fever, no worsening pain, and no signs of ongoing infection at the surgical site.
  • Monomicrobial Infection: An infection caused by a single type of microorganism, in this case, only Staphylococcus aureus.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs. In this trial, some patients may receive a saline solution instead of PP1493.

References

  1. http://clinicaltrials.eu/trial/study-on-phage-therapy-with-pp1493-pp1815-and-sodium-chloride-for-patients-with-hip-or-knee-joint-infections-from-staphylococcus-aureus/